Sarepta Corp - SRPT Bozor kapitallashuvining balans qiymatiga nisbati
Sarepta Therapeutics, Inc. (SRPT) uchun quyidagi kotirovkalar dori vositalarining patent himoyasi tufayli pul oqimi barqaror qolgan kompaniya dinamikasini aks ettiradi. Biznes bolalar patologiyalari uchun terapiyalarni ishlab chiqishda shifoxonalar bilan hamkorlikka tayanadi va joriy ko'rsatkich 1.30 ni tashkil etadi. Tsikllilikning butunlay yo'qligi va makroiqtisodiy omillardan mustaqillik ushbu sog'liqni saqlash sektorini g'oyat barqaror qiladi, chunki talab faqat hayotiy zarurat bilan belgilanadi.
%20Kapitallashuvning%20balans%20qiymatiga%20nisbati&width=1200&height=400&colorIndex=0&v=mvvwvvs9.gq-7b28iyo&start=20220704&end=20261031&filename=GURU_Markets_-_SRPT_-_Sarepta-Therapeutics-Inc._-_Capitalization-to-Book-Value-Ratio "SRPT: sarepta.com Bozor qiymatining balans qiymatiga nisbati 04.07.2022 - 31.10.2026 | 👁️GURU.Markets👁️")
Sarepta Therapeutics (SRPT) boʻyicha maʼlumotlarning jamlanma tahliliy kesimlari
- aksiya narxi va baholash bo'yicha konsensus prognoz:
- emitentning bozor qiymati haqida ma'lumotlar:
- buxgalteriya balansi bo'yicha sof aktivlar qiymati ko'rsatkichlari:
- qarzlar va to'lov qobiliyati haqida ma'lumot:
Qarzning xususiy kapitalga nisbati Sarepta Therapeutics, Inc.|SRPT - Uzoq muddatli qarzdorlikning kapitalga nisbati|Qisqa muddatli qarzning kapitalga nisbati Sarepta Therapeutics Inc|SRPT - Kompaniyaning jamlangan qarzlari|Qarzning balans kapitallashuviga nisbati Sarepta Therapeutics Inc|SRPT - Kompaniyaning uzoq muddatli kredit va qarzlari|Kompaniyaning qisqa muddatli qarzlari Sarepta|Tezkor likvidlik sarepta.com
- foyda va bozor multiplikatorlari tafsilotlari:
Kompaniyaning dastlabki tahlili:Sarepta Therapeutics, Inc.
Investorlar aktivlarning adolatli qiymatiga nisbatan premiumlarini baholash va biznesning haddan tashqari qimmat baholanishi xavfini aniqlash uchun ushbu koeffitsiyentdan foydalanadilar. Bozor kapitalizatsiyasining sof aktivlarning balans qiymatiga nisbati, ya'ni narxning balans qiymatiga nisbati koeffitsiyenti, sanksiya risklarining yo'qligi va gen terapiyasi sektoridagi ishlab chiqarish zanjirlarining ishonchliligi tufayli Sarepta Therapeutics, Inc. (SRPT) uchun barqaror qolmoqda.
Sarepta Therapeutics, Inc. kimlar bilan raqobatlashadi
TEM (Tempus Labs) - Kapitallashuvning sof aktivlarga nisbati|QGEN: Bozor kapitallashuvining balans qiymatiga multiplikatori|IONS (Ionis) - Bozor kapitallashuvining balans qiymatiga nisbati|Kapitallashuvning balans qiymatiga nisbati RGEN (Repligen Corp)|Bozor qiymatining balans qiymatiga nisbati Avidity (RNA)|CRISPR - Kapitallashuvning balans qiymatiga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati WGS (GeneDx Holdings Corp.)|Bozor kapitallashuvining balans qiymatiga nisbati ultragenyx.com RARE|BEAM - Bozor qiymatining balans qiymatiga nisbati|Balans qiymatiga nisbatan bozor kapitallashuvi Twist Bioscience Inc TWST|TXG: Bozor kapitallashuvining balans qiymatiga nisbati|Intellia Corp (NTLA) - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga nisbati Stoke Therapeutics|BLFS: Balans qiymatiga nisbatan bozor qiymati|Bozor kapitallashuvining balans qiymatiga nisbati WVE|MAZE - Bozor qiymatining balans qiymatiga koeffitsiyenti|Bozor qiymatining balans qiymatiga nisbati Sionna Pharma SION|PRME (Prime Medicine Bio) - Sof aktivlarga nisbatan bozor kapitallashuvi|TSHA: Kapitallashuvning sof aktivlarga nisbati|uniqure.com - Bozor kapitallashuvining balans qiymatiga multiplikatori|MGTX: Bozor kapitallashuvining balans qiymatiga nisbati|REGENXBIO Inc (RGNX) - Bozor kapitallashuvining balans qiymatiga nisbati|Kapitallashuvning sof aktivlarga nisbati SLDB|OCGN: Balans qiymatiga nisbatan bozor qiymati|Kapitallashuvning sof aktivlarga nisbati PACB (Pacific Biosciences)|Bozor kapitallashuvining balans qiymatiga multiplikatori BNTC|Bozor kapitallashuvining balans qiymatiga nisbati DSGN (Design Therapeutics, Inc.)|Balans qiymatiga nisbatan bozor qiymati RCKT|4D Molecular Therapeutics Inc - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga koeffitsiyenti Lexeo Therapeutics|korrobio.com (KRRO) - Bozor qiymatining balans qiymatiga nisbati|editasmedicine.com - Balans qiymatiga nisbatan bozor qiymati|SLN (Silence Therapeutics plc) - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati ProQR Therapeutics NV|Bozor qiymatining balans qiymatiga nisbati Codexis, Inc. (CDXS)|SGMO: Sof aktivlarga nisbatan bozor kapitallashuvi|Bozor kapitallashuvining balans qiymatiga nisbati NAUT (Nautilus Bio)|metagenomi.co (MGX) - Bozor qiymatining balans qiymatiga koeffitsiyenti|DTIL: Kapitallashuvning sof aktivlarga nisbati|GBIO - Bozor kapitallashuvining balans qiymatiga nisbati|BOLD (Boundless Bio, Inc) - Kapitallashuvning sof aktivlarga nisbati|XCUR: Bozor kapitallashuvining balans qiymatiga multiplikatori|IMNN (Imunon Inc) - Bozor kapitallashuvining balans qiymatiga nisbati|RXi Pharmaceuticals (PHIO) - Balans qiymatiga nisbatan bozor kapitallashuvi|Bozor kapitallashuvining balans qiymatiga nisbati MBIO|Kapitallashuvning sof aktivlarga nisbati transcodetherapeutics.com RNAZ|Bozor qiymatining balans qiymatiga nisbati Bionano Genomics BNGO|Balans qiymatiga nisbatan bozor kapitallashuvi Applied DNA Corp (APDN)|BLUE: Kapitallashuvning sof aktivlarga nisbati|Balans qiymatiga nisbatan bozor qiymati IPA (ImmunoPrecise Antibodies)|OMGA: Bozor kapitallashuvining balans qiymatiga nisbati|OMIC - Balans qiymatiga nisbatan bozor kapitallashuvi|Bozor qiymatining balans qiymatiga nisbati Regulus Therapeutics Inc|Kapitallashuvning balans qiymatiga nisbati SYRS (Syros Pharmaceuticals, Inc)|Bozor kapitallashuvining balans qiymatiga nisbati TBIO|Kapitallashuvning sof aktivlarga nisbati traconpharma.com TCON|Unity Biotechnology, Inc. - Kapitallashuvning sof aktivlarga nisbati